jueves, 27 de diciembre de 2018

Biotech's comeback kid: Endocyte, which Novartis just acquired for $2.1 bn

Biotech's comeback kid: Endocyte, which Novartis just acquired for $2.1 bn

Daily Recap



STAT Plus: 2018’s comeback kid: Endocyte goes from nosedive to Novartis’ latest acquisition

By KATE SHERIDAN


ADOBE
Last year, Endocyte laid off nearly half the company. This year, shareholders voted to approve a $2.1 billion acquisition offer from Novartis.

No hay comentarios:

Publicar un comentario